z-logo
open-access-imgOpen Access
How and when does an anticancer drug leave its binding site?
Author(s) -
Pratyush Tiwary,
Jagannath Mondal,
B. J. Berne
Publication year - 2017
Publication title -
science advances
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.928
H-Index - 146
ISSN - 2375-2548
DOI - 10.1126/sciadv.1700014
Subject(s) - molecular dynamics , salt bridge , dasatinib , biophysics , hydrogen bond , chemistry , drug discovery , ligand (biochemistry) , computational biology , drug , molecule , stereochemistry , biology , computational chemistry , biochemistry , tyrosine kinase , receptor , mutant , pharmacology , organic chemistry , gene
Obtaining atomistic resolution of drug unbinding from a protein is a much sought-after experimental and computational challenge. We report the unbinding dynamics of the anticancer drug dasatinib from c-Src kinase in full atomistic resolution using enhanced sampling molecular dynamics simulations. We obtain multiple unbinding trajectories and determine a residence time in agreement with experiments. We observe coupled protein-water movement through multiple metastable intermediates. The water molecules form a hydrogen bond bridge, elongating a specific, evolutionarily preserved salt bridge and enabling conformation changes essential to ligand unbinding. This water insertion in the salt bridge acts as a molecular switch that controls unbinding. Our findings provide a mechanistic rationale for why it might be difficult to engineer drugs targeting certain specific c-Src kinase conformations to have longer residence times.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom